Pharma-Bio Capital Prognosis: Signs of Life with $12 Billion in Active Grassroot Projects

Pharma-Bio Capital Prognosis: Signs of Life with $12 Billion in Active Grassroot Projects

Pharma-Bio Capital Prognosis: Signs of Life with $12 Billion in Active Grassroot Projects


Attachment: Top 10 States for Pharma-Biotech Industry Grassroot Plant Construction

SUGAR LAND--May 22, 2008--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Pharmaceutical plant closures continue to make headlines across the country, with thousands of jobs imperiled once the doors finally close. The financial and emotional impact on surrounding communities and residents resulting from the loss of a major employer is almost incalculable. Yet, even as companies continue to shed redundant sites and deem others as unnecessary because of age and myriad other factors, there are definite signs of life in the industry. A recent survey taken from Industrial Info's Pharmaceutical Tracker reveals 132 active grassroot construction projects in North America with an impressive total investment value of just over $12 billion.

Subscribe Now!(All Fields Required)

Standard Membership - Free